It is made available under a CC-BY-NC-ND 4.0 International license .

1	Title page
2	
3	Title: The phenotypic spectrum of terminal 6q deletions based on a large cohort derived from social
4	media and literature: a prominent role for <i>DLL1</i>
5	
6	Aafke Engwerda ¹ , Wilhelmina S. Kerstjens-Frederikse ¹ , Nicole Corsten-Janssen ¹ , Trijnie Dijkhuizen ¹
7	and Conny M. A. van Ravenswaaij-Arts ^{1, 2}
8	
9	
10	¹ University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen,
11	the Netherlands
12	² ATN/Jonx, Groningen, the Netherlands
13	
14	
15	Author to whom correspondence should be addressed:
16	Conny M.A. van Ravenswaaij-Arts
17	Department of Genetics, University Medical Center Groningen,
18	PO Box 30.001, 9700 RB Groningen, the Netherlands
19	Telephone: +31 50 361700
20	c.m.a.van.ravenswaaij@umcg.nl
21	

22

It is made available under a CC-BY-NC-ND 4.0 International license .

23 Abstract

24	Background: Terminal 6q deletions are rare, and the number of well-defined published cases is
25	limited. Since parents of children with these aberrations often search the internet and unite via
26	international social media platforms, these dedicated platforms may hold valuable knowledge about
27	additional cases. The Chromosome 6 Project is a collaboration between researchers and clinicians at
28	the University Medical Center Groningen and members of a Chromosome 6 support group on
29	Facebook. The aim of the project is to improve the surveillance of patients with chromosome 6
30	aberrations and the support for their families by increasing the available information about these
31	rare aberrations. This parent-driven research project makes use of information collected directly
32	from parents via a multilingual online questionnaire. Here, we report our findings on 93 individuals
33	with terminal 6q deletions and 11 individuals with interstitial 6q26q27 deletions, a cohort that
34	includes 38 newly identified individuals.
35	Results: Using this cohort, we can identify a common terminal 6q deletion phenotype that includes
36	microcephaly, dysplastic outer ears, hypertelorism, vision problems, abnormal eye movements,
37	dental abnormalities, feeding problems, recurrent infections, respiratory problems, spinal cord
38	abnormalities, abnormal vertebrae, scoliosis, joint hypermobility, brain abnormalities
39	(ventriculomegaly/hydrocephaly, corpus callosum abnormality and cortical dysplasia), seizures,
40	hypotonia, ataxia, torticollis, balance problems, developmental delay, sleeping problems and
41	hyperactivity. Other frequently reported clinical characteristics are congenital heart defects, kidney
42	problems, abnormalities of the female genitalia, spina bifida, anal abnormalities, positional foot
43	deformities, hypertonia and self-harming behaviour. The phenotypes were comparable up to a
44	deletion size of 7.1 Mb, and most features could be attributed to the terminally located gene DLL1.
45	Larger deletions that include QKI (>7.1 Mb) lead to a more severe phenotype that includes additional
46	clinical characteristics.

47

It is made available under a CC-BY-NC-ND 4.0 International license .

48	Conclusions : Terminal 6q deletions cause a common but highly variable phenotype. Most clinical
49	characteristics can be linked to the smallest terminal 6q deletions that include the gene <i>DLL1</i> (>500
50	kb). Based on our findings, we provide recommendations for clinical follow-up and surveillance of
51	individuals with terminal 6q deletions.
52	
53	Keywords: chromosome 6, terminal 6q deletion, 6q26, 6q27, DLL1, QKI, social media, patient
54	participation, parent-reported phenotype
55	
56	
57	Background
58	Terminal 6q deletions are a variable group of chromosome disorders, with the largest deletions
59	extending from 6q25.2 to 6qter (up to 16 Mb in size) and the smallest deletions restricted to the
60	most distal band 6q27 (as small as 390 kb in size) ¹ . As these deletions are rare, there is only limited
61	information about their effect on the clinical phenotype. This lack of knowledge impairs the ability of
62	health professionals to guide these individuals and their families.
63	To date, two large reviews on terminal 6q deletions have been published. Hopkin et al.
64	(1997) described 26 individuals with deletions in the 6q25q27 region. These individuals were
65	diagnosed by conventional cytogenetic methods, and interstitial deletions including only the
66	proximal part of 6q27 were also considered to be terminal ² . Lee et al. (2011) described another 28
67	individuals with pure terminal 6q deletions diagnosed by conventional cytogenetic methods or array
68	CGH, with all findings confirmed by FISH 3 . The individuals described in these two reviews presented
69	with a variable phenotype including brain abnormalities, hydrocephalus, microcephaly, seizures,
70	intellectual disability, hyperactivity/attention deficit hyperactivity disorder (ADHD), hypotonia, club
71	feet, genital hypoplasia, retinal abnormalities, cleft palate, dimpling on elbows and knees and facial
72	dysmorphisms including ear anomalies, broad nasal tip, prominent nasal bridge, epicanthic folds and
73	short palpebral fissures ^{2,3} .

It is made available under a CC-BY-NC-ND 4.0 International license .

74	Whereas earlier studies mostly used conventional cytogenetic methods, detailed microarray
75	techniques are now the routine diagnostic method. The robust and detailed microarray technique
76	allows for reliable comparisons of cytogenetic results from all over the world. In contrast,
77	international collection of detailed phenotypes lags behind the collection of genetic data because
78	only a minority of rare chromosomal aberration cases are submitted to international databases like
79	DECIPHER (https://www.deciphergenomics.org), and case reporting relies on health professionals
80	having the time and willingness to submit information. As a result, clinical information is often
81	incomplete.
82	Nowadays parents of individuals with a rare disorder often start searching the internet for
83	more information, and these parents frequently unite on social media platforms. In 2013, we started
84	the Chromosome 6 Project, a successful collaboration with a Chromosome 6 parent support group on
85	Facebook ⁴ . The Chromosome 6 Project allowed us to study detailed clinical information for 35 newly
86	identified individuals with terminal 6q deletions. The addition of information about 58 individuals
87	reported in literature who were diagnosed by a high-resolution cytogenetic technique allowed us to

describe the phenotype based on eight subgroups with different sizes of terminal 6q deletions. We
could also describe the phenotype of interstitial 6q26 and 6q27 deletions by including three newly
identified individuals and eight cases from the literature. Where relevant, we discuss the candidate

91 genes for specific clinical characteristics.

Our large cohort of 93 individuals with terminal 6q deletions allowed us to describe the most clinically relevant phenotype and define the effect of deletion size on this phenotype. Based on this data, it appears that deletion of the gene *DLL1* (Delta-Like Canonical Notch Ligand 1, MIM*606582) plays the most prominent causal role in the terminal 6q deletion phenotype. Our clinical description also leads to recommendations for clinical follow-up and surveillance that will enable healthcare professionals to better inform families and provide the best possible guidance to individuals with terminal 6q deletions.

99

It is made available under a CC-BY-NC-ND 4.0 International license .

100 Methods

101	To describe the terminal 6q deletion phenotype, we collected detailed genotype and phenotype data
102	on as many individuals as possible. The recruitment of individuals via social media, collection of
103	clinical information directly from parents (parent cohort), collection of patients extracted from the
104	literature (literature cohort) and data analysis were performed as described previously ⁴ and are
105	outlined in short below.
106	
107	Parent cohort
108	Individuals were informed about the Chromosome 6 Project and approached to participate via
109	Facebook (Chromosome 6 Facebook group), Twitter (@C6study) and our website
110	(https://www.chromosome6.org). Patients or their legal representatives could participate by signing
111	up via our secured website. Participants received a personal account for the online Chromosome 6
112	Questionnaire if there was an isolated chromosome 6 aberration and a microarray report was
113	available. Informed consent was obtained through the questionnaire. This procedure was ethically
114	waived by the accredited Medical Ethics Review Committee of the University Medical Center
115	Groningen.
116	Genotype data was extracted from the microarray reports, which were uploaded as part of
117	the sign-up procedure. These microarray analyses were performed in diagnostic laboratories using
118	different platforms. The UCSC LiftOver Tool was used to convert the microarray results to
119	GRCh37/hg19, and the UCSC genome browser was used to visualise the results
120	(http://genome.ucsc.edu).
121	In the current study we focus on participants with a terminal 6q deletion: a deletion
122	extending to the end of 6q, defined as including the most distally located gene (PDCD2,
123	MIM *600866), or an interstitial deletion within the 6q26q27 region (161,000,001–171,115,067).
124	Phenotype information on pregnancy and birth, congenital abnormalities, relevant
125	dysmorphic features, development, behaviour and health of the child was collected via the

- 126 multilingual online Chromosome 6 Questionnaire, which was constructed with the MOLGENIS
- 127 toolkit⁵. Clinical photographs and additional consent for publication were collected. Data collected
- 128 from individuals in the parent cohort was submitted to the DECIPHER database
- 129 (https://decipher.sanger.ac.uk) IDs 489709–489746.
- 130

131 Literature cohort

- 132 Case reports involving terminal 6q deletions were collected using PubMed and the following search
- 133 criteria: (deletion or monosomy) and (6q26 or 6q27 or terminal 6q). The references were then
- 134 checked for additional relevant case reports. Publications reporting detailed clinical information and
- 135 microarray results or comparably detailed breakpoint analyses were included. Clinical information
- 136 was extracted from the reports using the items of the Chromosome 6 Questionnaire.
- 137

138 Participant characteristics and genotypes

139 Up to September 2021, the Chromosome 6 Questionnaire was completed and submitted by 129 140 parents, and this included information on 38 individuals with aberrations in the region of interest for 141 this paper. Of these 38, 35 individuals (27 females and 8 males) had a terminal 6g deletion. Another 3 142 individuals (2 females and 1 male) had an interstitial deletion within the 6q26q27 region. Our 143 literature cohort comprises 58 terminal 6g deletion cases (34 females and 24 males) and 8 interstitial 6q26q27 cases (2 females and 6 males) derived from 29 published papers^{1,6–33}. In total, 93 terminal 144 145 6q deletion cases and 11 interstitial 6q26q27 cases were collected. The median age (years;months) of 146 individuals in the parent cohort was 4;6 (range 0;6-32;9) and 12;0 (range 0;0-57;0) in the literature 147 cohort. Data on foetuses was included both in the parent cohort (1 foetus; 23 weeks gestation) and 148 the literature cohort (7 foetuses; median 24 (range 14-30) weeks gestation). For six out of eight of 149 these cases, it was known that the pregnancy was terminated. For the foetus included in the parent 150 cohort, the parents gave us consent to fill out the Chromosome 6 Questionnaire based on the

151 ultrasound and autopsy results. Since the pregnancy was terminated, not all questions could be

152 completed.

Although we focused on isolated terminal and interstitial deletions in the 6q26q27 region, some small additional rearrangements of other chromosomes were included based on their size and gene content.

156

157 Data analysis

158 Clinical and behavioural characteristics were described as being present, absent or unknown. They

are presented here as present/known, where known indicates knowledge of presence or absence.

160 The developmental delay (intelligent quotient (IQ)) was categorised as normal (>85), borderline (70–

161 85), mild (50–70), moderate (30–50) or severe (<30) for individuals above the age of 2 years. This was

based on formal IQ tests or, if these were not available, the mean of the developmental quotients for

163 the milestones 'walking independently' and 'using two-word sentences'. The developmental

164 quotients were calculated as the 50th centile of the population age of achievement for that milestone

divided by the age of that achievement by the participant times 100. The 50th centiles of the

166 population age of achievement for the milestones 'walking independently' and 'using two-word

sentences' are 12³⁴ and 21 months³⁵, respectively. For specific milestones, the age and range of

achievement were presented, and we used a Mann-Whitney U-test to calculate whether there was a

significant difference in the age of milestone achievement between individuals with smaller (those

170 not including the gene QKI) and larger (those including QKI) terminal deletions.

171 The clinical characteristics of all terminal deletions were described as one group, but we also

172 describe subgroups made to provide information on differently sized deletions and interstitial

deletions separately. The terminal 6q deletion subgroups were based on the number of genes

174 involved with a predicted haploinsufficiency (HI) effect. To determine whether genes had a predicted

175 HI-effect, we used HI- and loss-of-function intolerance (pLI) scores as described previously

176 ⁴(https://www.deciphergenomics.org)³⁶ (http://exac.broadinstitute.org)³⁷, see Table S1. Genes with a

177	HI score <10% and/or a pLI score ≥0.9 were considered HI-genes. The terminal 6q26q27 region
178	contains eight such HI-genes: TBP, PSMB1, DLL1, AFDN, PDE10A, QKI, PRKN and MAP3K4. This
179	allocation resulted in eight terminal 6q deletion subgroups: T-PSMB1 (including PSMB1 and TBP), T-
180	DLL1, T-AFDN, T-PDE10A, T-QKI, T-PRKN, T-MAP3K4 and a residual group (T-R) that includes deletions
181	extending beyond 6q26 and including the HI-gene IGF2R (Figure 1). Two subgroups of interstitial
182	deletions were described: interstitial deletions of 6q26 (I-6q26) and interstitial deletions of 6q27 (I-
183	6q27) (Figure 1). The phenotypes of individuals with a terminal 6q deletion due to a ring
184	chromosome were compared to those with a simple terminal deletion. We also investigated how
185	often breakpoints in the fragile site FRAE6 (6q26) were present in terminal 6q deletions in order to
186	explore its involvement in breakpoint occurrence.
187	
188	Results
189	All individuals were assigned to one of the ten subgroups based on the number of HI-genes present
190	in their terminal 6q deletion or the cytogenetic location of the interstitial deletion. Figure 1 visualises
191	the deletions, subgroups and HI-genes. The main genotype characteristics of the subgroups are
192	summarised in Table 1. The phenotype information is summarised in Table 2 (see supplementary
193	Table S2, for details). Information on development is given in Table 3 and visualised in Figure 2 and
194	Figure S1. Below, we provide a phenotype description for the whole group of terminal 6q deletions,
195	with subgroups highlighted when specific clinical characteristics were only seen in the subgroups
196	with larger terminal deletions. Descriptions of the most prominent characteristics in the interstitial
197	6q26q27 deletions are given separately. In the Discussion, we briefly consider the role of the deleted
198	genes in the phenotype, if applicable.

200 The terminal 6q deletion phenotype

201 The pregnancy was characterised by intrauterine growth restriction in 30% of individuals and 202 reduced foetal movements in 26% of individuals. Prolonged neonatal jaundice was reported in 9/30 203 new-borns with a terminal deletion including PDE10A (larger than 5 Mb). 204 Many individuals had a small head size (<p10) (60%) and/or plagiocephaly (47%). Some 205 individuals had a short body stature (<p10) (30%). Dysmorphisms included hypertelorism (51%), 206 dysplastic ears (51%) and dental abnormalities (38%). A cleft lip and/or palate was seen in three 207 individuals with larger deletions, see Table S2. One individual (T-R) also had a choanal stenosis. 208 Decreased visual acuity (67%) was mostly mild (16/30). Abnormal eye movements (56%) 209 included strabismus (24/30) and nystagmus (11/30). Aplasia/hypoplasia of the optic nerve was seen 210 in 4/26 individuals with a deletion including at least *PRKN* (larger than 7.9 Mb). Microphthalmos (2/4) 211 and coloboma (1/4) were only seen with the largest deletions, subgroup T-R (larger than 10.5 Mb). 212 Feeding problems (72%) were common, with oral aversion (61%), chewing difficulties (43%), 213 dysphagia (39%) and gastroesophageal reflux (26%) most often reported. Seven individuals needed a 214 gastrostomy, and all seven had a deletion including PRKN. Bowel problems (43%), often constipation 215 (32%), were also reported, but never for the smallest deletions, subgroup T-DLL1 (smaller than 2.7 216 Mb). Five out of 24 individuals with a deletion including the gene QKI (larger than 7.1 Mb) had an 217 abnormality of the anus, either anal atresia (n=3) or an ectopic anus (n=1). 218 Recurrent infections (42%) were often reported, including of the upper respiratory tract 219 (13/13). Respiratory problems were reported in 26% of the individuals. Sleep apnoea (n=3) was only 220 present in deletions including at least QKI. Congenital heart defects (CHDs) (12/42), kidney problems 221 (7/37) and abnormalities of the female genitalia (6/27) were only reported in individuals with a

deletion including AFDN (larger than 2.7 Mb).

A sacral dimple was reported in 23/31 individuals with a deletion including *AFDN*. Spina bifida was seen in 5/21 individuals with a deletion including *PRKN* (larger than 7.9 Mb). Scoliosis (6/39) and abnormal vertebrae (8/38, including hemivertebrae in n=4) were seen throughout the whole group. Joint hypermobility was present in 64% of all individuals, and hip dysplasia was reported in 6/15

individuals with a *PDE10A* deletion. In individuals with a deletion including *AFDN*, a positional foot

deformity (8/14) and pes planus (5/14) were reported.

229 Almost all individuals had brain abnormalities on MRI or CT (91%). Those most often reported 230 were ventriculomegaly/hydrocephaly (51/72), corpus callosum abnormalities (31/72), abnormalities of the cerebellum (18/72) and cortical dysplasia (15/72). In literature, other brain abnormalities were 231 232 reported that were not included in the Chromosome 6 Questionnaire, these included colpocephaly 233 (n=8), periventricular nodular heterotopia (PNH) (n=6), hypoplasia of the hippocampi (n=5) and a large cisterna magna (n=5), and all were seen throughout all subgroups^{7,9,20,26,28}. Seizures (67%) 234 235 (generalised (16/44) and focal onset (20/44)) were often reported, and epilepsy was formally 236 diagnosed in 83% of individuals with seizures. Hypotonia (83%) was very common. Hypertonia was 237 reported in 7/29 individuals, and most of these individuals had a deletion including at least PRKN. 238 3/17 individuals with a *PRKN* deletion were reported with spasticity. Balance problems (71%) were 239 often seen. Torticollis (26%), ataxia (38%) and spinal cord abnormalities (39%) were reported 240 throughout the whole group, as well as abnormal pain sensation (30%) and sensory integration 241 disorder (30%). 242 Behaviour was most often described as being social (60%), helpful (29%), easily upset (40%) 243 and hyperactive (36%). Seven out of 22 individuals with a *PRKN* deletion showed self-harming 244 behaviour. Half of the individuals had sleeping problems (50%), most frequently insomnia (67%). 245 Almost all individuals had developmental delay (92%), see Table 3 and Figure S1. Five 246 individuals had no developmental delay, and their ages ranged from 5–49 years and their deletion sizes from 2–5.5 Mb, see Figure S1^{16,20}. The level of developmental delay varied considerably within 247 248 all the subgroups, but was mostly mild to moderate. Individuals without a deletion of QKI (deletion 249 smaller than 7.1 Mb) had normal development to moderate delay, and individuals with a deletion 250 including QKI (larger than 7.1 Mb) had borderline to severe developmental delay.

Ages of achievement for certain milestones are summarised in Table 4 and visualised in Figure 2. All children with a deletion not including *QKI* (smaller than 7.1 Mb) were able to perform

253	the milestone 'walking independently' at age 3 years and the milestone 'using two-word sentences'
254	at age 4 years. For individuals with larger deletions including <i>QKI</i> (larger than 7.1 Mb), some needed
255	more time to achieve these milestones and one individual was not yet able to walk independently at
256	age 12 years. The milestones 'roll over', 'sit up unaided' and 'pull up in a standing position' were
257	achieved significantly earlier by children with deletions that did not include QKI. Five out of 22
258	children reached the milestone 'fully toilet trained during the day' at age 4 years.
259	Two out of seven index patients with an inherited deletion (subgroups T-DLL1 and T-AFDN),
260	inherited this from an independently functioning parent (1 maternal, 1 paternal) ²⁰ .
261	Nineteen out of 93 individuals had reached adulthood, and their median age was 32 years
262	(range 18–57). Detailed information on adult functioning could only be collected for two adults from
263	the parent cohort. One individual needed help with all tasks and was not able to take care of herself
264	(T-PRKN). The other adult (T-PRKN) was able to perform simple tasks (for example handling a phone
265	and performing some daily housework) but needed assistance with most tasks.
266	Some clinical characteristics were reported in literature that were not part of the
267	Chromosome 6 Questionnaire. In addition to the brain abnormalities reported above, micrognathia
268	and high arched palate were reported in 13 and 14 individuals in literature, respectively ^{1,7-}
269	^{10,13,19,23,26,28} . These characteristics could also not be related to deletion size.
270	

271 Interstitial 6q26 and 6q27 deletion phenotype

272 All five interstitial 6q27 deletion individuals were derived from literature, and the only deleted HI-

273 gene they had in common was *DLL1* (Figure 1). Their phenotype was mostly characterised by brain

abnormalities (ventriculomegaly/ hydrocephaly, corpus callosum abnormality and cortical dysplasia),

275 epilepsy and mild developmental delay. Other characteristics reported were small head size,

276 strabismus, horseshoe kidney, joint hypermobility, hypotonia, ataxia and autistic behaviour.

277 There were three interstitial 6q26 deletion individuals in the parent cohort and another three

278 in the literature cohort. *PRKN* was involved in all deletions, and the largest deletion also

279	encompassed QKI and PDE10A (Figure 1). Individuals with 6q26 interstitial deletions were mostly
280	characterised by a normal head size and normal body stature, brain abnormalities (delayed
281	myelination, ventriculomegaly/hydrocephaly), vision problems, feeding problems, an abnormal
282	curvature of the spine (scoliosis/kyphosis), hypotonia and insomnia. Other characteristics reported
283	were atrial septal defect (ASD), hydronephrosis, constipation, spina bifida, epilepsy and sleep
284	apnoea. Their behaviour was mostly characterised by social behaviour, hyperactivity, attention
285	deficit disorder and autistic behaviour/disorder. One individual presented self-harming behaviour.
286	Three individuals had no developmental delay, one had borderline delay and one had mild delay
287	(Figure S1 and Table 3).
288	
289	Ring 6 phenotype
290	For two individuals, their terminal deletion was known to be the result of a ring chromosome 6 ^{23,32} .
291	The ring also included a small terminal 6p deletion without phenotypic consequences ³⁸ . There were
292	no differences in the phenotype between the individuals with a ring chromosome and individuals
293	with a comparable simple deletion.
294	
295	Effect of the common fragile site FRA6E
296	None of the 93 terminal deletions had a start breakpoint within the fragile site FRA6E (Figure 1).
297	
298	Discussion
299	Here we have reported our findings on rare chromosome 6q deletions in the region 6q26q27, which
300	are mainly terminal 6q deletions. Below, we summarise the most clinically relevant characteristics
301	and provide advice about additional medical examinations, follow-up and surveillance. We also
302	briefly discuss the genes involved in the deletions and, based on what is known about these genes,
303	how they could be linked to the observed clinical characteristics. We found that there is only a minor
304	effect of deletion size on the clinical phenotype, resulting in a common (but variable) phenotype

seen in all terminal 6q deletion individuals. This commonality could be explained by the prominent
 role of the distally located gene *DLL1*, with only individuals with deletions larger than 7.1 Mb clearly

307 showing additional or more severe clinical characteristics.

308 In our cohorts there is a clear common terminal 6g deletion phenotype characterised by a 309 small head size, dysplastic outer ears, hypertelorism, vision problems, abnormal eye movements, 310 dental abnormalities, feeding problems, recurrent infections, respiratory problems, spinal cord 311 abnormalities, abnormal vertebrae, scoliosis, joint hypermobility, brain abnormalities 312 (ventriculomegaly/hydrocephaly, corpus callosum abnormality and cortical dysplasia), seizures, 313 hypotonia, ataxia, torticollis, balance problems, developmental delay, sleeping problems and 314 hyperactivity. Since these characteristics are common in the affected individuals, it is most likely that 315 the phenotype is caused by haploinsufficiency of the most distally located genes. Nonetheless, the 316 phenotype is very variable, and not all characteristics are seen in all individuals.

317 The three most distally located HI-genes that could contribute to this common 6q terminal 318 deletion phenotype are TBP (Tata Box-Binding Protein, MIM*600075), PSMB1 (Proteasome Subunit 319 Beta-Type 1, MIM*602017) and DLL1. TBP is known to cause late-onset neurological disorders such 320 as spinocerebellar ataxia (MIM#607136) and Parkinson's disease (MIM#168600) through expansion of a CAG repeat³⁹, but it is unclear whether loss of function of one allele has a phenotypic affect. 321 322 Mice haploinsufficient for *Tbp* did not show any abnormalities⁴⁰, and no pathogenic loss-of-function 323 variants have been reported in humans. For the gene PSMB1, no pathogenic heterozygous variants 324 have been reported. Recently, a presumed pathogenic homozygous missense variant was reported resulting in microcephaly, developmental delay and short stature in two sisters, aged 22 and 35 325 326 years⁴¹. These clinical characteristics are present in our cohort but also appear in individuals with an interstitial 6q27 deletion that did not involve *PSMB1^{7,29}*. Furthermore, there are multiple individuals 327 with a deletion including both *TBP* and *PSMB1* in the database of genomic variance $(DGV)^{42}$. The 328 329 presence of these deletions in people with a normal or unrelated phenotype makes it unlikely that 330 *TBP* or *PSMB1* play a major role in the terminal 6g deletion phenotype.

It is made available under a CC-BY-NC-ND 4.0 International license .

331

332 <u>DLL1</u>

333	The third distally located HI-gene of interest for the common 6q terminal deletion phenotype is <i>DLL1</i> .
334	Recently, Fischer-Zirnsak et al. (2019) described 14 patients with pathogenic heterozygous variants of
335	DLL1 and one patient with a deletion including DLL1. These patients presented with hypotonia,
336	scoliosis and a neurodevelopmental phenotype including variable brain abnormalities
337	(ventriculomegaly/hydrocephaly, corpus callosum abnormality and cortical dysplasia), seizures and
338	autism spectrum disorder ²⁹ . This phenotype was registered in OMIM as neurodevelopmental
339	disorder with nonspecific brain abnormalities and with or without seizures (NEDBAS,
340	OMIM#618709). Additionally, the following clinical characteristics were reported in at least one
341	patient with a heterozygous DLL1 variant: PNH, large cisterna magna, strabismus, feeding problems,
342	sleep apnoea, recurrent infections, hemivertebrae, sacral dimple, joint hypermobility, ataxia and
343	hyperactivity ²⁹ . As all these clinical characteristics are also seen in our terminal 6q deletion cohorts, it
344	is very likely that haploinsufficiency of <i>DLL1</i> makes an important contribution to the common
345	terminal 6q deletion phenotype. Lesieur-Sebellin et al. characterised the features detected by
346	prenatal ultrasound in 22 foetuses with terminal 6q deletions and pointed out the gene <i>DLL1</i> as the
347	major contributor to the detected phenotype ⁴³ .
348	In 2005, Eash et al. reported a patient (Eash_1) with the smallest terminal deletion seen thus
349	far, 390kb, which only included the HI-genes <i>TBP</i> and <i>PSMB1</i> ¹ . This patient's phenotype was
350	comparable to the common terminal 6q deletion phenotype we describe and included microcephaly,
351	brain abnormalities (corpus callosum abnormality, hydrocephaly), seizures, vertebral abnormalities,
352	hypotonia and developmental delay (Tables 2, 3 and S2; subgroup T-PSMB1). Most other
353	characteristics of the common terminal 6q deletion phenotype were not reported as being present or
354	absent in the Eash et al. case. The breakpoints of this deletion where defined by BAC and PAC FISH
355	clones at approximately 500 kb intervals ¹ . If the possible maximum size of the deletion is taken into
356	consideration (Figure 1), the <i>DLL1</i> gene could actually be part of the deletion. We tried contacting

357 the authors about additional genetic studies performed for this individual, but without success.

358 Considering the overlapping phenotype and the ambiguities in breakpoint definition, we expect that

359 *DLL1* is also part of, or influenced by, the deletion in this case.

360 DLL1 codes for a ligand of the Notch receptor. The Notch signalling developmental pathway is 361 involved in cell-to-cell communication and cell patterning and differentiation. Notch signalling plays a 362 role in the development of multiple organs and tissues, including the somite-derived organs, nervous system, heart, vasculature, haematopoietic system, cochlea and pancreas⁴⁴. In our cohorts, we did 363 364 not clearly see any abnormalities for the four latter organ systems, but the nervous system, somite-365 derived organs and heart were affected. 366 In mice, delayed expression of *Dll1* leads to premature cell differentiation, resulting in a smaller brain and fused vertebrae and ribs⁴⁵. This is in line with the variable brain abnormalities, 367

368 microcephaly and abnormalities of the vertebrae seen in our cohorts and in the heterozygous *DLL1*

369 variant patients reported by Fischer-Zirnsak et al.²⁹.

370 CHDs were not reported in the patients by Fischer-Zirnsak et al.²⁹ and also not seen in our T-371 DLL1 subgroup, so the effect on heart development may not be fully penetrant. We did find CHDs in 372 larger deletions that include DLL1. In these patients, DLL1 seems the most likely candidate gene to 373 cause CHDs given its role in the Notch pathway and reported pathogenic variants in NOTCH1 in 374 patients with a CHD⁴⁶. During heart development, Notch signalling plays a crucial role in the formation of the membranous walls of the atrial and ventricular chambers and of the outflow tract⁴⁷. 375 376 Interruption in Notch signalling could explain the CHDs in our cohorts: ASDs, VSDs and a coarctation 377 of the aorta in one individual. Bu et al. reported a patient with an ASD and persistent left superior 378 vena cava with a heterozygous DLL1 variant that was classified as likely pathogenic. This DLL1 variant patient also had a cleft palate, but no further phenotype information was given⁴⁸. A cleft palate was 379 380 also seen in two of our patients, although these two had the largest terminal deletions of our cohort.

381

382 Other genes

383 Besides *DLL1*, other genes were also previously proposed to play a role in the terminal 6q deletion

384 phenotype, especially in larger terminal deletions that display additional clinical characteristics.

385 Below, we briefly summarise these in the context of our findings.

386 Several genes have been linked to brain abnormalities. *ERMARD* (Endoplasmic Reticulum

387 Membrane-Associated RNA Degradation Protein, MIM*615532 (also known as C6orf70)) might be

388 involved in PNH, since Conti et al. described nine patients with a deletion including ERMARD and one

389 patient with a heterozygous missense variant and PNH⁷. Unfortunately, we do not have information

390 on the prevalence of PNH for our parent cohort. One patient in our literature cohort did present with

391 PNH, but her deletion did not include *ERMARD*²⁸. *ERMARD* is also not a predicted HI-gene (%HI:

392 84.86, pLI: 0.00). Based on this information and the fact that the deletion patients presenting with

393 PNH of Conti et al. all had a deletion that also included *DLL1*, it remains unclear whether

394 haploinsufficiency of *DLL1* or *ERMARD*, or both, can cause PNH.

395 Peddibhotla et al. suggested two other genes that may be involved in structural brain

abnormalities: THBS2 (Thrombospondin II, MIM*188061) and PHF10 (Phd Finger Protein 10,

397 MIM*613069). These genes were deleted in all seven of their terminal 6q deletion patients⁹.

398 However, both genes are not predicted HI-genes, and no pathogenic variants causing structural brain

abnormalities in humans have been described thus far.

400 Lastly, *QKI* has been linked to brain abnormalities because it plays a role in myelination by

401 regulating several myelin-specific genes⁴⁹. Five individuals in our terminal 6q deletion cohort

402 presented with delayed myelination, and all have a *QKI* deletion (Figure S2). One individual with an

403 interstitial 6q26 deletion also presents with delayed myelination, but QKI is not part of her deletion,

404 and 32 out of 37 patients with a deletion of QKI did not have delayed myelination. Likewise, Backx et

405 al. reported a woman with a reciprocal balanced translocation t(5;6)(q23.1;q26) disrupting the QKI

406 gene, resulting in 50% reduced QKI expression, who did not present with myelination problems⁵⁰.

407 Thus, although it is likely that *QKI* plays a role in myelination, there seems to be incomplete

408 penetrance of this clinical feature.

It is made available under a CC-BY-NC-ND 4.0 International license .

409	Vertebral abnormalities are part of the common terminal 6q deletion phenotype, and TBXT
410	(T-Box Transcription Factor T, MIM*601397) is suggested to play a role in the aetiology of
411	hemivertebrae ¹⁸ . An identical missense variant in this gene was identified in three unrelated patients
412	with congenital vertebral malformations. This variant was proposed to increase the risk of congenital
413	vertebral malformations, but not sufficiently on its own ^{18,51} . Nevertheless, <i>TBXT</i> was not deleted in all
414	patients with hemivertebrae in our cohort. We therefore think this phenotype is more likely linked to
415	DLL1.
416	Dental problems, including abnormal morphology and reduced number of teeth, are also
417	part of the common terminal 6q deletion phenotype. The gene SMOC2 is related to dental problems
418	in carriers of pathogenic homozygous variants, including oligodontia, microdontia and abnormally
419	shaped teeth ⁵²⁻⁵⁴ . However, no pathogenic heterozygous <i>SMOC2</i> variants have been identified thus
420	far, and SMOC2 was not deleted in all individuals with dental problems in our cohort (Figure S3).
421	CHDs were seen in 12 patients with terminal deletions including at least AFDN (deletions
422	larger than 2.7 Mb). Next to <i>DLL1</i> , these deletions also included the gene <i>THBS2</i> . In two large CHD
423	cohort studies, two variants of unknown significance in THBS2 were found. One patient presented
424	with a tetralogy of Fallot ⁵⁵ . The other patient presented with subaortic stenosis, bicuspid aortic valve,
425	mitral valve stenosis and regurgitation and a coarctation of the aorta ⁵⁶ . In contrast, our CHD patients
426	mainly presented with septal defects. Since there is no further proof for the role of THBS2 in CHD,
427	and all terminal 6q deletions also include the more likely candidate gene DLL1, we regard the
428	contribution of THBS2 to CHD in the 6q deletion phenotype as less likely.
429	Recent work showed that <i>QKI</i> also plays a role in cardiovascular development and function in
430	mice and might be involved in cardiomyopathies and cardiovascular disease in humans ⁵⁷ . One (1/42)
431	of our patients (aged <5 years) with a deletion including <i>QKI</i> was reported to have hypertrophic
432	cardiomyopathy. Further research is needed to investigate whether there is a relation between
433	cardiomyopathies and a deletion of <i>QKI</i> and thus whether individuals with a <i>QKI</i> deletion need to be

434 screened for cardiomyopathy.

It is made available under a CC-BY-NC-ND 4.0 International license .

435	Almost all the individuals in our cohort with a deletion including <i>DLL1</i> had developmental
436	delay. Besides DLL1, QKI seems to mark a tipping point in the extent of developmental delay. Normal
437	development was seen in a couple of individuals without a deletion of <i>QKI</i> , whereas severe
438	developmental delay was only seen in individuals with a deletion including <i>QKI</i> (Figure S1, Table 3).
439	The woman with a reciprocal balanced translocation t(5;6)(q23.1;q26) disrupting the <i>QKI</i> gene
440	reported by Backx et al. also presented with borderline developmental delay ⁵⁰ . QKI probably has an
441	additive effect on the level of developmental delay next to the deletion of DLL1, which on its own can
442	lead to moderate developmental delay in small (500 kb) deletions ²⁸ .
443	A range of behavioural problems was seen throughout the whole group of terminal deletions,
444	with information available for all 34 individuals from the parent cohort but only 8 of 51 literature
445	cases, foetuses excluded (Table S2). Self-harming behaviour was seen significantly (Fisher's Exact Test
446	p=0.03) more often in the larger terminal deletions. Fischer et al. reported autism spectrum disorder
447	as part of the syndrome linked to <i>DLL1</i> haploinsufficiency. In their cohort, 5 out of their 13 <i>DLL1</i>
448	variant patients and their one <i>DLL1</i> deletion patient had autism spectrum disorder ²⁹ . In our cohorts,
449	however, autistic behaviour was present in only 4/33 individuals with a terminal deletion including
450	DLL1. However, autistic behaviour was also seen in 3/5 individuals with an interstitial 6q26 deletion
451	that did not include <i>DLL1</i> , suggesting that <i>DLL1</i> haploinsufficiency is not the only cause for autistic
452	behaviour.
453	The individuals with terminal 6q deletions included in our cohort were grouped based on the
454	number of predicted HI-genes involved in their deletion. However, only two HI-genes, DLL1 and QKI,
455	could be linked to some of the observed clinical characteristics. This is reflected in the phenotypic
456	differences between the patients with deletions smaller and larger than 7.1 Mb.

457

458 <u>FRA6E</u>

459 It has been suggested that the *FRA6E* fragile site is the cause of the breakpoints in terminal 6q
460 deletions^{3,12,13}. *FRA6E* is a common fragile site located at 161.71–161.91 Mb in 6q26 (Figure 1).

It is made available under a CC-BY-NC-ND 4.0 International license .

461 Common fragile sites are associated with hotspots for chromosome aberration breakpoints⁵⁸ due to 462 an impaired replication process at the fragile site. Nevertheless, Palumbo et al. showed that the 463 replication process at *FRAGE* is not impaired⁵⁹, and we also do not see a clustering of breakpoints

- 464 within or near the fragile site in our data.
- 465

466 **Recommendations for clinical follow-up and surveillance**

467 The common terminal 6q deletion phenotype is highly variable, and not all clinical characteristics are

present in each individual. Therefore clinical follow-up and surveillance should be focused on the

469 congenital anomalies present and the problems experienced. This also means that the phenotype

470 should be fully assessed upon diagnosis to establish which of the comorbidities known for this

471 chromosomal aberration are present in the patient. In Table 5, we present our recommendations for

- 472 investigations for terminal 6q deletions <7.1 Mb and for deletions >7.1 Mb including the gene QKI.
- 473 We recommend that all individuals should be offered a neurological investigation (including an MRI
- 474 upon indication), a cardiac ultrasound (at least once), an investigation by an ophthalmologist and an

475 annual vision assessment at younger ages and upon indication at older ages. As seizures are seen in a

476 large proportion of the individuals, the threshold should be low for consulting a (paediatric)

477 neurologist and for performing an EEG. Individuals with hypermobility can benefit from

478 physiotherapy and medical aids. For individuals with deletions >7.1 Mb, clinicians should also be

aware of the occurrence of cleft palate, anal atresia and sleep apnoea, which are reported in some

480 individuals and can be treated. Some individuals with deletions >7.1 Mb have spina bifida, although

481 vertebral abnormalities that could cause scoliosis are seen for all deletion sizes. Performing an X-ray

482 of the vertebral column can help identify these abnormalities. Besides this specific advice for

individuals with a terminal 6q deletion, appropriate support for feeding, behavioural and sleeping

484 problems should also be in place.

485 Development was delayed in most individuals, and those with deletions >7.1 Mb needed 486 more time to achieve developmental milestones than those with deletions <7.1 Mb. Nonetheless, all

It is made available under a CC-BY-NC-ND 4.0 International license .

- 487 but one individual did achieve the milestones 'walking independently' and 'using two-word
- 488 sentences' (Table 4 and Figure 2). As in all neurodevelopmental disorders, the definite aim should be
- 489 to optimise the developmental abilities and quality of life of the individual with a chromosomal
- 490 aberration and their family. Having more detailed information available on what to expect is an
- 491 important step in this process.

492

493 **Table 5.** Clinical recommendations for terminal 6q deletions

Deletion size	<7.1 Mb		>7.1 Mb	
	Upon diagnosis	Follow-up	Upon diagnosis	Follow-up
Full neurological examination, including balance	+	i	+	i
MRI	i	i	i	i
Be aware of seizures	+	+	+	+
EEG	i	i		i
Be aware of abnormal pain sensation	+	+	+	+
Vision assessment, including strabismus	+	a / i*	+	a / i*
Be aware of coloboma/optic nerve			+	
Hearing assessment	i	i	i	i
Cardiac ultrasound	+	i	+	i
Be aware of sleep appoea	•	•	+	+
Be aware of cleft (soft) palate			+	
Dental abnormalities	+	i	+	i
Assess feeding problems, including reflux and				
constipation	+	i	+	i
Be aware of anal atresia			+	
Renal ultrasound	i	i		i
Be aware of recurrent respiratory tract	+	+	+	+
Be aware of scoliosis	+	+	+	+
X-ray to exclude vertebral abnormalities	i	i	+#	i
Be aware of joint hypermobility	+	+	+	+
Including hip dysplasia	+	i	+	i
Assess development	+	i	+	i
Be aware of sleeping problems	+	+	+	+
Assess behavioural problems	+	i	+	i

494 + = to be performed, a = annual, i = upon indication

495 *Annually at young age and upon indication at later ages

- 496 [#]Also be aware of spina bifida occulta
- 497

498 Limitations of the study and suggestions for future research

It is made available under a CC-BY-NC-ND 4.0 International license .

499	Recruiting parents via social media and collecting phenotypes directly from the parents via the online
500	Chromosome 6 Questionnaire resulted in an extensive dataset for the parent cohort. However, not
501	all clinical characteristics were addressed in literature, resulting in missing data. For example, it was
502	only known for one out of ten (10%) individuals in the T-PDE10A subgroup if they had sleeping
503	problems, while this was known for 14 out of 20 (70%) in the T-PRKN subgroup. The main difference
504	between these subgroups was the ratio of parent cohort versus literature cohort cases, which was
505	1:9 for T-PDE10a and 15:5 for T-PRKN. In another study, we investigated the availability of data on
506	specific phenotype information in literature case reports compared to data collected directly from
507	parents in the terminal 6q deletion cohort presented here. We show that we collected significantly
508	more data from parents, for almost all phenotypic features, in comparison to the literature ⁶⁰ .
509	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be
509 510	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort
509 510 511	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these
509 510 511 512	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these balance problems in individuals with a deletion including <i>PRKN</i> (larger than 7.9 Mb) (5/16, 31%). It
509 510 511 512 513	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these balance problems in individuals with a deletion including <i>PRKN</i> (larger than 7.9 Mb) (5/16, 31%). It remains unknown whether vestibular and/or cerebellar dysfunctions only cause balance problems in
509 510 511 512 513 514	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these balance problems in individuals with a deletion including <i>PRKN</i> (larger than 7.9 Mb) (5/16, 31%). It remains unknown whether vestibular and/or cerebellar dysfunctions only cause balance problems in patients with larger deletions, or if the causes of balance problems in those with smaller deletions
509 510 511 512 513 514 515	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these balance problems in individuals with a deletion including <i>PRKN</i> (larger than 7.9 Mb) (5/16, 31%). It remains unknown whether vestibular and/or cerebellar dysfunctions only cause balance problems in patients with larger deletions, or if the causes of balance problems in those with smaller deletions were simply not investigated or reported.
509 510 511 512 513 514 515 516	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these balance problems in individuals with a deletion including <i>PRKN</i> (larger than 7.9 Mb) (5/16, 31%). It remains unknown whether vestibular and/or cerebellar dysfunctions only cause balance problems in patients with larger deletions, or if the causes of balance problems in those with smaller deletions were simply not investigated or reported. Our phenotype data was collected directly from parents, which might raise questions on the
509 510 511 512 513 514 515 516 517	A risk of not reporting data on absent phenotype features is that incorrect conclusions can be drawn. For example, balance problems were often reported in the whole terminal 6q deletion cohort (25/35, 71%), but vestibular and/or cerebellar dysfunction was only reported as a cause of these balance problems in individuals with a deletion including <i>PRKN</i> (larger than 7.9 Mb) (5/16, 31%). It remains unknown whether vestibular and/or cerebellar dysfunctions only cause balance problems in patients with larger deletions, or if the causes of balance problems in those with smaller deletions were simply not investigated or reported. Our phenotype data was collected directly from parents, which might raise questions on the quality of the data. However, in our data consistency study we show that phenotype data collected

519 individual⁶⁰.

Another topic for which information is still very limited is the natural history of disease and adulthood. For two individuals with a terminal 6q deletion smaller than 2.7 Mb, it is known that they did not have developmental delay and could live independently. For another two individuals with a deletion larger than 7.9 Mb (including *PRKN*), it is known that they could not (fully) take care of themselves and could not live independently. However, for most individuals who have reached

It is made available under a CC-BY-NC-ND 4.0 International license .

adulthood, information on their level of performance is very limited and it was unclear whether they

- 526 could live independently. Follow-up on adults with terminal 6q deletions is needed to give insight
- 527 into adult functioning and development of new clinical features at older ages.
- 528 Our recommendations for investigations now focus on two groups deletions <7.1 Mb and
- deletions >7.1 Mb including the gene QKI since this was a clear tipping point in the reported
- 530 phenotypes. However, we cannot be absolutely sure that these clinical characteristics are only seen
- in the larger deletions and will never be reported in individuals with smaller deletions. Therefore we
- have tried to be cautious in our recommendations for investigations. Since the phenotype can be
- 533 very variable, it is important to assess each patient on an individual level. Nonetheless, the general
- differences we have reported can be helpful in counselling (expecting) parents. For the future, we
- bob hope to be able to give more detailed recommendations based on deletion sizes, but this is only
- possible if detailed information for an even larger study population is collected.

537

538 Conclusions

- 539 Terminal 6q deletions cause a common phenotype that is broad and highly variable within individuals
- 540 and within families. The main clinical characteristics are microcephaly, brain abnormalities
- 541 (ventriculomegaly/hydrocephaly, corpus callosum abnormalities and cortical dysplasia), neurological
- 542 problems (seizures, hypotonia and ataxia), vision problems, developmental delay, behavioural
- 543 problems and subtle dysmorphic features. Cardiac, gastrointestinal, urogenital and skeletal
- anomalies may also occur. Most of the characteristics can be linked to the distally located gene DLL1
- and, probably as a consequence, deletion size has little effect on the phenotype. However,
- 546 individuals with deletions >7.1 Mb that include QKI present with a more severe phenotype that
- 547 includes severe developmental delay. Based on our findings, we provide recommendations for
- clinical follow-up and surveillance of individuals with terminal 6q deletions. To further improve these
- recommendations, more data needs to be collected, especially on clinical follow-up and adult
- 550 functioning.

It is made available under a CC-BY-NC-ND 4.0 International license .

551

- 552
- 553 List of abbreviations
- 554 ASD = atrial septal defect
- 555 ADHD = attention deficit hyperactivity disorder
- 556 CHD = congenital heart defect
- 557 DGV = database of genomic variance
- 558 HI = haploinsufficiency
- 559 pLI = loss-of-function intolerance
- 560 PNH = periventricular nodular heterotopia

561

- 562 Declarations
- 563 <u>Ethics approval and consent to participate</u>
- 564 The accredited Medical Ethics Review Committee of the University Medical Center Groningen waived
- 565 full ethical evaluation because, according to Dutch guidelines, no ethical approval is necessary if
- 566 medical information that was already available is used anonymously and no extra tests have to be
- 567 performed.
- 568
- 569 <u>Consent for publication</u>
- 570 Consent for publication was obtained from all participants, and additional consent was obtained for
- 571 the use of photographs.

572

573 Availability of data and materials

574 Data collected from individuals in the parent cohort was submitted to the DECIPHER database

575 (decipher.sanger.ac.uk), IDs 489709–489746.

It is made available under a CC-BY-NC-ND 4.0 International license .

577 Competing interests

- 578 The authors declare no competing interests
- 579
- 580 <u>Funding</u>
- 581 This work was supported by a grant from ZonMw (113312101) and by crowd-funding organised by
- 582 Chromosome 6 parents. AE is recipient of a Junior Scientific Masterclass MD/PhD scholarship of the
- 583 University Medical Center Groningen.
- 584
- 585 <u>Authors' contributions</u>
- 586 Conceptualisation: AE, CMAR; Data curation: AE; Funding acquisition: AE, CMAR; Investigation: AE,
- 587 CMAR; Methodology: AE, CMAR; Project administration: AE; Resources: AE, CMAR; Software: AE;
- 588 Supervision: CMAR; Visualisation: AE; Writing original draft: AE; Writing review & editing: AE,
- 589 WSK, NC, TD, CMAR.
- 590

591 Acknowledgements

- 592 We would like to thank all the children and families for their participation. We also thank Kate
- 593 Mc Intyre for editing the manuscript, Nadia Simoes de Souza for helping with data collection and first
- analysis, Dr. Valerio Conti for providing patient information and Morris Swertz and the members of
- 595 the MOLGENIS team at the Groningen Genomic Coordination Center for their support on the online
- 596 Chromosome 6 Questionnaire. Our special thanks go to Pauline Bouman, our contact for the
- 597 Chromosome 6 Facebook group.

598

599

600 References

- 1. Eash D, Waggoner D, Chung J, Stevenson D, Martin CL. Calibration of 6q subtelomere deletions
- to define genotype/phenotype correlations. Clin Genet. 2005;67(5):396–403.

- 603 2. Hopkin RJ, Schorry E, Bofinger M, Milatovich A, Stern HJ, Jayne C, et al. New insights into the
- 604 phenotypes of 6q deletions. Am J Med Genet. 1997;70(4):377–86.
- 605 3. Lee JY, Cho YH, Hallford G. Delineation of Subtelomeric Deletion of the Long Arm of
- 606 Chromosome 6: 6q Subtelomeric Deletion. Ann Hum Genet. 2011 Nov;75(6):755–64.
- 607 4. Engwerda A, Frentz B, den Ouden AL, Flapper BCT, Swertz MA, Gerkes EH, et al. The phenotypic
- 608 spectrum of proximal 6q deletions based on a large cohort derived from social media and
- 609 literature reports. Eur J Hum Genet EJHG. 2018;(Journal Article).
- 5. Swertz MA, Dijkstra M, Adamusiak T, van der Velde JK, Kanterakis A, Roos ET, et al. The
- 611 MOLGENIS toolkit: rapid prototyping of biosoftware at the push of a button. BMC
- 612 Bioinformatics. 2010 Dec;11 Suppl 1:S12–S12.
- 613 6. Dupe V, Rochard L, Mercier S, Le Petillon Y, Gicquel I, Bendavid C, et al. NOTCH, a new signaling
- 614 pathway implicated in holoprosencephaly. Hum Mol Genet. 2011 Mar;20(6):1122–31.
- 615 7. Conti V, Carabalona A, Pallesi-Pocachard E, Parrini E, Leventer RJ, Buhler E, et al. Periventricular
- 616 heterotopia in 6q terminal deletion syndrome: Role of the C6orf70 gene. Brain.
- 617 2013;136(11):3378–94.
- 8. Striano P, Malacarne M, Cavani S, Pierluigi M, Rinaldi R, Cavaliere ML, et al. Clinical phenotype

and molecular characterization of 6q terminal deletion syndrome: Five new cases. Am J Med
Genet A. 2006 Sep;140A(18):1944–9.

- 621 9. Peddibhotla S, Nagamani SCS, Erez A, Hunter JV, Holder JL, Carlin ME, et al. Delineation of
- 622 candidate genes responsible for structural brain abnormalities in patients with terminal
- deletions of chromosome 6q27. Eur J Hum Genet. 2015;23(1):54–60.

- 624 10. Abu-Amero KK, Hellani A, Salih MA, Al Hussain A, al Obailan M, Zidan G, et al. Ophthalmologic
- abnormalities in a de novo terminal 6q deletion. Ophthalmic Genet. 2010 Mar;31(1):1–11.
- 626 11. Dobyns WB, Mirzaa G, Christian SL, Petras K, Roseberry J, Clark GD, et al. Consistent
- 627 chromosome abnormalities identify novel polymicrogyria loci in 1p36.3, 2p16.1-p23.1, 4q21.21-
- 628 q22.1, 6q26-q27, and 21q2. Am J Med Genet A. 2008;146(13):1637–54.
- 629 12. De Cinque M, Palumbo O, Mazzucco E, Simone A, Palumbo P, Ciavatta R, et al. Developmental
- 630 coordination disorder in a patient with mental disability and a mild phenotype carrying terminal
- 631 6q26-qter deletion. Front Genet. 2017;8(DEC):6–10.
- Bertini V, De Vito G, Costa R, Simi P, Valetto A. Isolated 6q terminal deletions: an emerging new
 syndrome. Am J Med Genet A. 2006 Jan;140(1):74–81.
- Quelin C, Saillour Y, Poirier K, Roubertie A, Boddaert N, Desguerre I, et al. Focal polymicrogyria
 are associated with submicroscopic chromosomal rearrangements detected by CGH microarray
 analysis. Eur J Med Genet. 2012;55(10):527–30.
- 637 15. Mosca AL, Callier P, Masurel-Paulet A, Thauvin-Robinet C, Marle N, Nouchy M, et al.
- 638 Cytogenetic and array-CGH characterization of a 6q27 deletion in a patient with developmental
- delay and features of Ehlers-Danlos syndrome. Am J Med Genet A. 2010;152(5):1314–7.
- 640 16. Gerber JC, Neuhann TM, Tyshchenko N, Smitka M, Hackmann K. Expanding the clinical and
- 641 neuroradiological phenotype of 6q27 microdeletion: Olfactory bulb aplasia and anosmia. Am J
- 642 Med Genet A. 2011;155(8):1981–6.
- 643 17. Li P, Pomianowski P, DiMaio MS, Florio JR, Rossi MR, Xiang B, et al. Genomic characterization of
- 644 prenatally detected chromosomal structural abnormalities using oligonucleotide array
- 645 comparative genomic hybridization. Am J Med Genet A. 2011 Jul;155(7):1605–15.

- 18. Li Y, Choy KW, Xie HN, Chen M, He WY, Gong YF, et al. Congenital Hydrocephalus and
- 647 Hemivertebrae Associated with de NOVO Partial Monosomy 6q (6q25.3→qter). Balk J Med
 648 Genet. 2015;
- 649 19. Valduga M, Philippe C, Bach Segura P, Thiebaugeorges O, Miton A, Beri M, et al. A retrospective
- 650 study by oligonucleotide array-CGH analysis in 50 fetuses with multiple malformations. Prenat
- 651 Diagn. 2010 Apr;30(4):333–41.
- 652 20. Wadt K, Jensen LN, Bjerglund L, Lundstrøm M, Kirchhoff M, Kjaergaard S. Fetal
- ventriculomegaly due to familial submicroscopic terminal 6q deletions. Prenat Diagn. 2012
- 654 Dec;32(12):1212-7.
- 655 21. Kraus J, Lederer G, Keri C, Seidel H, Rost I, Wirtz A, et al. A familial unbalanced subtelomeric
- translocation resulting in monosomy 6q27→qter. J Med Genet. 2003 Apr;40(4):e48 LP-e48.
- Rigon C, Salviati L, Mandarano R, Donà M, Clementi M. 6q27 subtelomeric deletions: Is there a
 specific phenotype? Am J Med Genet A. 2011;155(5):1213–4.
- 23. Liu S, Wang Z, Wei S, Liang J, Chen N, Ouyang H, et al. Gray Matter Heterotopia, Mental
- 660 Retardation, Developmental Delay, Microcephaly, and Facial Dysmorphisms in a Boy with Ring
- 661 Chromosome 6: A 10-Year Follow-Up and Literature Review. Cytogenet Genome Res. 2018;
- Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence of genes and
 cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet.
- 664 2014;94(5):677–94.
- 665 25. Schumann M, Hofmann A, Krutzke SK, Hilger AC, Marsch F, Stienen D, et al. Array-based
- 666 molecular karyotyping in fetuses with isolated brain malformations identifies disease-causing 667 CNVs. J Neurodev Disord. 2016;

668	26.	Rooms L, Rey	yniers E, Wu	uyts W, Storm K	, van Luijk R	, Scheers S	, et al. Mul	tiplex ligation-
-----	-----	--------------	--------------	-----------------	---------------	-------------	--------------	------------------

669 dependent probe amplification to detect subtelomeric rearrangements in routine diagnostics.

670 Clin Genet. 2006;

- 671 27. Thakur M, Bronshtein E, Hankerd M, Adekola H, Puder K, Gonik B, et al. Genomic detection of a
- 672 familial 382 Kb 6q27 deletion in a fetus with isolated severe ventriculomegaly and her affected
- 673 mother. Am J Med Genet A. 2018;
- 674 28. Hanna MD, Moretti PN, De Oliveira PC, Rosa AMT, Versiani RB, De Oliveira SF, et al. Defining
- the critical region for intellectual disability and brain malformations in 6q27 microdeletions.

676 Mol Syndromol. 2019;

- 677 29. Fischer-Zirnsak B, Segebrecht L, Schubach M, Charles P, Alderman E, Brown K, et al.
- 678 Haploinsufficiency of the Notch Ligand DLL1 Causes Variable Neurodevelopmental Disorders.

679 Am J Hum Genet. 2019 Sep 5;105(3):631–9.

- 680 30. Scheuerle A, Wilson K. PARK2 copy number aberrations in two children presenting with autism
- 681 spectrum disorder: further support of an association and possible evidence for a new
- 682 microdeletion/microduplication syndrome. Am J Med Genet Part B Neuropsychiatr Genet Off
- 683 Publ Int Soc Psychiatr Genet. 2011 Jun;156B(4):413–20.
- 684 31. Puvabanditsin S, Negroponte E, Jang P, Hedges A, Kased R, Mehta R. Multiple Congenital
- Anomalies in a Patient with Interstitial 6q26 Deletion. Mol Syndromol. 2020 Jan;10(5):276–80.
- 686 32. Ciocca L, Surace C, Digilio MC, Roberti MC, Sirleto P, Lombardo A, et al. Array-CGH
- 687 characterization and genotype-phenotype analysis in a patient with a ring chromosome 6. BMC
- 688 Med Genomics. 2013 Dec;6(1):3.

- 689 33. Auber B, Bruemmer V, Zoll B, Burfeind P, Boehm D, Liehr T, et al. Identification of subtelomeric
- 690 genomic imbalances and breakpoint mapping with quantitative PCR in 296 individuals with
- 691 congenital defects and/or mental retardation. Mol Cytogenet. 2009;2(1):10–10.
- 692 34. Group WMGRS, de Onis M. WHO Motor Development Study: Windows of achievement for six
- 693 gross motor development milestones. Acta Paediatr. 2006;95(S450):86–95.
- 694 35. Bayley. Bayley scales of infant development¹: manual. San Antonio: Psychological corporation;
 695 1969.
- Huang N, Lee I, Marcotte EM, Hurles ME. Characterising and predicting haploinsufficiency in the
 human genome. PLoS Genet. 2010;6(10):e1001154–e1001154.
- 698 37. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-

coding genetic variation in 60,706 humans. Nature. 2016 Aug;536(7616):285–91.

- 700 38. Rraku E, Kerstjens-Frederikse WS, Swertz MA, Dijkhuizen T, Ravenswaaij-Arts CMA van,
- 701 Engwerda A. The phenotypic spectrum of terminal and subterminal 6p deletions based on a
- social media-derived cohort and literature review. Manuscr Submitt Orphanet J Rare Dis. 2022;
- 703 39. Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, et al. A Neurological
- 704 Disease Caused By an Expanded CAG Trinucleotide Repeat in The TATA-Binding Protein Gene: A

705 New Polyglutamine Disease? Hum Mol Genet. 1999 Oct 1;8(11):2047–53.

- 40. Martianov I, Viville S, Davidson I. RNA Polymerase II Transcription in Murine Cells Lacking the
 TATA Binding Protein. Science. 2002 Nov 1;298(5595):1036–9.
- Ansar M, Ebstein F, Özkoç H, Paracha SA, Iwaszkiewicz J, Gesemann M, et al. Biallelic variants in
 PSMB1 encoding the proteasome subunit β6 cause impairment of proteasome function,

710		microcephaly, intellectual disability, developmental delay and short stature. Hum Mol Genet.
711		2020 May 8;29(7):1132–43.
712	42.	MacDonald JR, Ziman R, Yuen RKC, Feuk L, Scherer SW. The Database of Genomic Variants: a
713		curated collection of structural variation in the human genome. Nucleic Acids Res. 2014 Jan
714		1;42(Database issue):D986–92.
715	43.	Lesieur-Sebellin M, Till M, Khau Van Kien P, Herve B, Bourgon N, Dupont C, et al. Terminal 6q
716		deletions cause brain malformations, a phenotype mimicking heterozygous DLL1 pathogenic
717		variants: A multicenter retrospective case series. Prenat Diagn [Internet]. [cited 2022 Jan
718		8];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pd.6074
719	44.	Siebel C, Lendahl U. Notch Signaling in Development, Tissue Homeostasis, and Disease. Physiol
720		Rev. 2017 Oct 1;97(4):1235–94.
721	45.	Shimojo H, Isomura A, Ohtsuka T, Kori H, Miyachi H, Kageyama R. Oscillatory control of Delta-
722		like1 in cell interactions regulates dynamic gene expression and tissue morphogenesis. Genes
723		Dev. 2016 Jan 1;30(1):102–16.
724	46.	Kerstjens-Frederikse WS, van de Laar IMBH, Vos YJ, Verhagen JMA, Berger RMF, Lichtenbelt KD,
725		et al. Cardiovascular malformations caused by NOTCH1 mutations do not keep left: data on 428
726		probands with left-sided CHD and their families. Genet Med. 2016 Sep 1;18(9):914–23.
727	47.	Luxán G, D'Amato G, MacGrogan D, de la Pompa JL. Endocardial Notch Signaling in Cardiac
728		Development and Disease. Circ Res [Internet]. 2016 Jan 8 [cited 2021 Jul 5];118(1). Available
729		from: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.115.305350
730	48.	Bu H, Liu L, Hu S, Tan Z, Zhao T. Targeted next Igeneration sequencing for research and
731		diagnostics in congenital heart disease, and cleft lip and/or palate. Mol Med Rep. 2019 May
732		1;19(5):3831–40.

733	49.	Thangaraj MP, Furber KL, Gan JK, Ji S, Sobchishin L, Doucette JR, et al. RNA-binding Protein
734		Quaking Stabilizes Sirt2 mRNA during Oligodendroglial Differentiation. J Biol Chem. 2017 Mar
735		31;292(13):5166–82.
736	50.	Backx L, Fryns JP, Marcelis C, Devriendt K, Vermeesch J, Van Esch H. Haploinsufficiency of the
737		gene Quaking (QKI) is associated with the 6q terminal deletion syndrome. Am J Med Genet A.
738		2010;
739	51.	Ghebranious N, Blank RD, Raggio CL, Staubli J, McPherson E, Ivacic L, et al. A Missense
740		T(Brachyury) Mutation Contributes to Vertebral Malformations. J Bone Miner Res.
741		2008;23(10):1576–83.
742	52.	AlFawaz S, Fong F, Plagnol V, Wong FSL, Fearne J, Kelsell DP. Recessive oligodontia linked to a
743		homozygous loss-of-function mutation in the SMOC2 gene. Arch Oral Biol. 2013 May
744		1;58(5):462–6.
745	53.	Bloch-Zupan A, Jamet X, Etard C, Laugel V, Muller J, Geoffroy V, et al. Homozygosity Mapping

and Candidate Prioritization Identify Mutations, Missed by Whole-Exome Sequencing, in
 SMOC2, Causing Major Dental Developmental Defects. Am J Hum Genet. 2011 Dec 9;89(6):773–

748 81.

54. McKusick-Nathans Institute of Genetic Medicine JHU (Baltimore MD). Online Mendelian
Inheritance in Man, OMIM[®] [Internet]. Vol. 2016. Available from: https://omim.org/

Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare inherited and de
novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017 Nov;49(11):1593–
601.

754	56.	Alankarage D, Ip E, Szot JO, Munro J, Blue GM, Harrison K, et al. Identification of clinically
755		actionable variants from genome sequencing of families with congenital heart disease. Genet
756		Med. 2019 May;21(5):1111–20.
757	57.	Chen X, Liu Y, Xu C, Ba L, Liu Z, Li X, et al. QKI is a critical pre-mRNA alternative splicing regulator
758		of cardiac myofibrillogenesis and contractile function. Nat Commun. 2021 Jan 4;12:89.
759	58.	Lukusa T, Fryns JP. Human chromosome fragility. Biochim Biophys Acta BBA - Gene Regul Mech.
760		2008 Jan 1;1779(1):3–16.
761	59.	Palumbo E, Matricardi L, Tosoni E, Bensimon A, Russo A. Replication dynamics at common
762		fragile site FRA6E. Chromosoma. 2010 Dec;119(6):575–87.
763	60.	Engwerda A, Frentz B, Rraku E, Simoes de Souza NF, Swertz MA, Plantinga M, et al. Parent-
764		reported phenotype data on chromosome 6 aberrations collected via an online questionnaire:
765		data consistency and data availability. Manuscr Submitt Orphanet J Rare Dis. 2022;
766		
767		
768	Figu	re 1. Overview of all terminal 6q deletions and interstitial 6q26q27 deletions. Deletions from our
769	pare	nt cohort (black bars) and literature cohort (grey bars) are shown, and their minimum (thick bar)
770	and	maximum (thin bar) deletion size are visualised when available. The terminal deletions are
771	divid	led into eight subgroups (shown on the right hand side) based on the most proximal gene with a
772	prec	licted haploinsufficiency effect (HI-gene) (vertical light blue lines) involved in the minimum
773	dele	tion size. T-PSMB1: terminal deletions only including <i>PSMB1</i> and <i>TBP</i> (breakpoint distal to 170.6
774	Mb)	, T-DLL1: terminal deletions including <i>DLL1</i> (breakpoint between 168.4 and 170.6 Mb), T-AFDN:
775	term	ninal deletions including AFDN (166.1–168.4 Mb), T-PDE10A: terminal deletions including PDE10A
776	(164	.0–166.1 Mb), T-QKI: terminal deletions including <i>QKI</i> (163.1–164.0 Mb), T-PRKN: terminal
777	dele	tions including PRKN (161.5–163.1 Mb), T-MAP3K4: terminal deletions including MAP3K4 (160.5–

778	161.5 Mb) and T-R (residual group): terminal deletions including <i>IGF2R</i> and larger (breakpoint
779	proximal to 160.5 Mb). Interstitial deletions are divided in two subgroups based on their cytogenetic
780	location: I-6q26: interstitial deletions (mostly) located on chromosome band 6q26 (161–164.5 Mb), I-
781	6q27: deletions located on chromosome band 6q27 (164.5–171.1 Mb). The deletions are visualised
782	using the UCSC genome browser (<u>https://genome.ucsc.edu</u>). The vertical red line marks the location
783	of the common fragile site FRA6E. The literature cases were derived from 29 reports ^{1,6–33} .
784	
785	Figure 2. Age of achievement for milestones 'walking independently' and 'using two-word
786	sentences' in participants who were at least 12 months of age. Deletions smaller than 7.1 Mb include
787	subgroups T-PSMB1, T-DLL1, T-AFDN and T-PDE10A. Deletions larger than 7.1 Mb include subgroups
788	T-QKI, T-PRKN, T-MAP3K4 and T-R. Light grey bars indicate the number of children (x axis) that have
789	reached the milestones 'walking independently' (upper panel) and 'using two-word sentences' (lower
790	panel) before the given age (y axis, years). The dark grey bars are the children who were not able to
791	perform the milestone at that age. The hatched bars are the children who were not able to perform
792	the milestone, but who have not yet reached the age on the y axis. For example, at age 12 years, 29–
793	47 (60–98%) participants are able to walk (figure and description adapted from Engwerda, et al.
794	2018 ⁴).
795	
796	Supplementary files
797 709	Figure S1. Developmental delay in children older than 2 years of age
198	rigure 52. Delayed Myelination

- 799 Figure S3. Dental problems
- 800
- 801 Table S1. HI and pLI scores
- 802 Table S2. Phenotypes detailed
- 803

Subgroup	Cohort parent/ literature	No. of foetuses	Age median* (range) years; months	Deletion size median (range) Mb	No. of OMIM genes median (range)	No. of HI genes median (range)
Total terminal (n=93)	35/58	8	7;5 (0;0–57;0)	6.45 (0.39–16.00)	25 (3–62)	4 (1–14)
Parent cohort	35/0	1	4;6 (0;6–32;9)	8.39 (0.76–16.00)	29 (5–62)	6 (2–14)
Literature cohort	0/58	7	12;0 (0;0–57;0)	4.14 (0.39–15.99)	22 (3–62)	3 (1–14)
T-PSMB1 (n=1)	0/1	0	8;0	0.39	3	1
T-DLL1 (n=23)	3/20	2	17;0 (0;0–49;0)	1.95 (0.53–2.66)	10 (5–12)	2
T-AFDN (n=16)	6/10	2	6;6 (0;6–57;0)	4.01 (3.07–4.97)	22 (14–24)	3
T-PDE10A (n=10)	1/9	0	3;10 (0;1–25;0)	5.89 (5.16–7.00)	25	4
T-QKI (n=7)	3/4	0	7;11 (0;8–25;0)	7.68 (7.37–7.84)	28 (27–28)	5
T-PRKN (n=20)	15/5	0	5;0 (0;4–32;9)	8.57 (8.09–9.53)	29 (29–30)	6
T-MAP3K4 (n=6)	4/2	2	6;3 (4;10–14;9)	10.14 (9.94–10.31)	33 (31–35)	7
T-R (n=10)	3/7	2	8;0 (0;6–37;0)	12.12 (10.79–16.00)	51.5 (40–62)	11.5 (8–14)
Total Interstitial	3/8	0				
(n=11)			6;0 (0;1–43;0)	0.33 (0.04–3.08)	2 (1–7)	1 (1–3)
Parent cohort	3/0	0	6;0 (2;2–15;4)	0.33 (0.21–3.08)	1(1-5)	1 (1–3)
Literature cohort	0/8	0	10;2 (0;1–43;0)	0.61 (0.04-1.18)	4.5 (1–7)	1
l-6q26 (n=6)	3/3	0	10;2 (0;1-19;0)	0.23 (0.04–3.08)	1.5 (1–5)	1 (1-3)
I-6q27 (n=5)	0/5	0	6;0 (1;6–43;0)	0.97 (0.12–1.18)	7 (2–7)	1

 Table 1. Genotype characteristics of terminal 6q and interstitial 6q26q27 deletions

*If known, foetuses were excluded from the age calculations

Genotype characteristics for all subgroups as represented in Figure 1. The number (median and range) of all OMIM genes (<u>https://www.omim.org</u>) and the genes with predicted haploinsufficiency effect (HI-genes) (<u>https://www.deciphergenomics.org</u>)³⁶³⁷ within the deletions are given.

It is made available under a CC-BY-NC-ND 4.0 International license

Group*	Т-			Т-		•	т.		Total		
Group	PSMB1	T-DI I 1	T-AFDN	PDF10A	Τ-ΟΚΙ	T-PRKN	ΜΔΡ3ΚΔ	T-R	terminal	l-6a27	I-6a26
Characteristics	(n=1)	(n=23)	(n=16)	(n=10)	(n=7)	(n=20)	(n=6)	(n=10)	(n=93)	(n=5)	(n=6)
Sex (female/male)	male	14/9	9/7	9/1	4/3	10/10	6/0	9/1	61/32	2/3	2/4
Prolonged neonatal jaundice	n.a.	0/3	0/5	1/3	1/4	, 6/15	1/4	0/4	9/38	0/0	0/5
Low birth weight (<p10)< td=""><td>+</td><td>0/5</td><td>3/9</td><td>0/5</td><td>1/6</td><td>5/15</td><td>1/4</td><td>2/3</td><td>13/48</td><td>0/1</td><td>1/4</td></p10)<>	+	0/5	3/9	0/5	1/6	5/15	1/4	2/3	13/48	0/1	1/4
Short stature (<p10)< td=""><td>+</td><td>1/7</td><td>1/9</td><td>2/7</td><td>0/5</td><td>6/15</td><td>1/3</td><td>3/3</td><td>15/50</td><td>0/1</td><td>0/2</td></p10)<>	+	1/7	1/9	2/7	0/5	6/15	1/3	3/3	15/50	0/1	0/2
Head circumference											
<p10 normal=""></p10> p90	<p10< td=""><td>5/4/2</td><td>2/5/1</td><td>4/2/2</td><td>5/1/1</td><td>13/3/0</td><td>1/1/0</td><td>3/0/1</td><td>34/16/7</td><td>1/0/0</td><td>0/2/0</td></p10<>	5/4/2	2/5/1	4/2/2	5/1/1	13/3/0	1/1/0	3/0/1	34/16/7	1/0/0	0/2/0
Plagiocephaly	n.a.	2/4	2/6	0/1	2/3	7/13	2/4	1/3	16/34	0/0	1/4
Hypertelorism	n.a.	3/8	4/8	3/4	4/6	8/18	2/3	4/8	28/55	1/2	1/3
Vision problems	n.a.	2/4	5/6	1/5	4/5	10/16	3/4	5/5	30/45	0/0	2/4
Mild vision problems	n.a.	1/2	3/5	0/1	3/4	6/10	2/3	1/5	16/30	0/0	1/2
Hypermetropia	n.a.	0/4	2/6	0/4	4/5	5/17	3/4	0/4	14/44	0/0	2/4
Nystagmus	-	0/5	2/8	0/5	2/6	3/18	2/4	2/6	11/53	0/1	1/4
Strabismus	+	1/5	4/8	1/5	3/6	8/18	2/4	4/6	24/53	1/1	0/4
Abnormal eye morphology	n.a.	0/3	1/5	0/4	0/4	7/16	0/4	4/6	12/42	0/0	0/3
Dysplastic outer ear	+	5/7	3/8	5/6	3/5	7/15	0/4	3/7	27/53	1/2	0/3
Cleft lip and/or palate	n.a.	0/9	0/6	0/5	0/5	1/13	0/4	2/7	3/49	0/1	0/2
Dental problems	n.a.	2/3	1/4	1/1	2/5	7/15	0/3	0/3	13/34	0/1	0/3
Feeding difficulties	n.a.	3/3	3/6	2/2	2/5	13/16	3/4	2/3	28/39	0/0	2/3
Constipation	n.a.	0/3	2/7	1/1	1/3	5/16	2/4	1/3	12/37	0/0	1/3
Anal abnormality	n.a.	0/3	0/6	0/1	1/3	4/14	0/4	0/3	5/34	0/0	0/3
Respiratory problems	n.a.	1/3	2/7	1/2	0/3	4/15	0/4	2/4	10/38	0/0	1/4
Recurrent infections	n.a.	2/4	1/5	0/1	2/3	5/11	2/4	1/3	13/31	0/0	1/3
Congenital heart defect	n.a.	0/3	1/6	3/5	0/6	6/17	0/4	2/4	12/45	0/0	1/5
Kidney abnormality	n.a.	0/3	2/7	0/3	1/3	2/16	1/4	1/4	7/40	1/1	1/4
Abnormal genitals in females	n.a.	0/1	1/6	0/1	1/3	3/10	0/4	1/3	6/28	0/0	0/2
Sacral dimple	n.a.	0/4	3/5	1/2	3/3	11/14	2/4	3/3	23/35	0/0	1/3
Spina bifida	n.a.	0/3	0/6	0/2	0/3	3/12	0/4	2/5	5/35	0/0	1/4
Spinal cord abnormality	n.a.	1/4	0/4	2/5	3/3	6/14	1/4	2/4	15/38	0/0	0/3

Table 2. Overview of most prominent characteristics seen in individuals with terminal 6q deletions and interstitial 6q26q27 deletions

It is made available under a CC-BY-NC-ND 4.0 International license

Abnormal vertebral	+	1/5	1/7	0/2	1/3	1/11	2/5	1/4	8/38	0/0	0/3
morphology											
Scoliosis	n.a.	1/6	0/6	0/2	2/4	3/14	0/4	0/3	6/39	0/0	1/5
Hip dysplasia	n.a.	0/1	0/1	1/2	0/1	5/10	0/1	0/1	6/17	0/0	0/1
Hypermobility of the joints	n.a.	3/4	9/11	2/3	3/5	8/17	4/4	3/6	32/50	1/1	0/3
Pes planus	n.a.	0/4	1/7	0/3	2/5	2/15	0/4	0/5	5/43	0/0	0/5
Positional foot deformity	n.a.	0/4	1/7	2/3	1/5	1/15	0/4	3/5	8/43	0/0	1/5
Capillary hemangioma	n.a.	0/5	1/5	0/3	0/4	1/13	1/4	0/3	3/37	0/1	0/4
Hypopigmentation of the skin	n.a.	0/5	0/5	1/3	0/4	1/13	1/4	0/3	3/37	0/1	0/4
Brain abnormalities on MRI or											
СТ	+	14/17	11/12	9/10	6/7	17/18	5/5	9/9	72/79	4/5	2/2
Ventriculomegaly and/or											
hydrocephaly	+	10/14	10/11	7/9	4/6	9/17	4/5	6/9	51/72	4/5	1/2
Abnormality of the											
cerebellum	-	0/14	4/11	1/9	2/6	5/17	3/5	3/9	18/72	2/5	0/2
Corpus callosum											
abnormality	+	4/14	1/11	5/9	3/6	8/17	2/5	7/9	31/72	3/5	0/2
Cortical dysplasia	-	4/14	1/11	2/9	2/6	4/17	1/5	1/9	15/72	4/5	0/2
Seizures and/or epilepsy	+	5/12	3/10	4/6	6/7	15/19	3/4	7/7	44/66	3/5	1/3
Focal-onset	+	1/5	2/3	0/4	4/6	5/15	2/3	5/7	20/44	3/3	0/1
Generalized-onset	-	3/5	1/3	0/4	5/6	4/15	2/3	1/7	16/44	0/3	0/1
Hypotonia	+	7/10	7/9	6/7	6/6	15/16	3/4	5/7	50/60	1/1	2/5
Hypertonia	n.a.	0/3	1/5	0/1	0/1	2/11	2/4	2/4	7/29	0/0	0/3
Ataxia	n.a.	2/4	1/5	1/1	1/3	2/10	2/3	2/3	11/29	1/1	0/3
Torticollis	n.a.	2/3	0/5	0/1	1/3	3/12	1/4	1/3	8/31	0/0	0/3
Balance problems	n.a.	3/4	2/6	2/2	2/3	11/13	3/4	2/3	25/35	0/0	1/3
Developmental delay (Table 3)	+	14/16	9/11	5/6	6/6	15/15	4/4	6/6	60/65	4/4	2/5
Sleeping problems	n.a.	1/3	4/7	0/1	3/4	7/14	2/4	1/3	18/36	0/0	2/4
Insomnia	n.a.	1/1	4/4	0/0	1/3	4/7	2/2	0/1	12/18	0/0	2/2
Social behaviour	n.a.	2/6	4/6	1/3	3/5	10/15	2/4	3/3	25/42	0/0	3/3
Helpful behaviour	n.a.	1/6	2/6	1/3	2/5	5/15	1/4	0/3	12/42	0/0	1/3
Easily upset	n.a.	3/6	3/6	1/3	2/5	4/15	2/4	2/3	17/42	0/0	1/3

It is made available under a CC-BY-NC-ND 4.0 International license .

	Hyperactivity	n.a.	3/6	1/6	1/3	1/5	6/15	1/4	2/3	15/42	0/0	2/3	
--	---------------	------	-----	-----	-----	-----	------	-----	-----	-------	-----	-----	--

*For explanation see Figure 1.

CT = computed tomography, MRI = magnetic resonance imaging, n.a. = not available

Clinical characteristics were selected based on prevalence and clinical significance. More details are presented in Supplementary Table S2

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license

									Total		
	T-PSMB1	T-DLL1	T-AFDN	T-PDE10A	T-QKI	T-PRKN	T-MAP3K4	T-R	(terminal)	I-6q27	I-6q26
Normal	0	2	2	1	0	0	0	0	5	0	3
Borderline	0	1	1	0	1	2	0	0	5	0	1
Mild delay	0	2	3	2	1	6	1	2	17	4	1
Moderate delay	0	6	1	1	3	2	1	2	16	0	0
Severe delay	0	0	0	0	1	1	0	0	2	0	0
Delayed but not specified Unknown due to	1	5	4	2	0	4	2	2	20	0	0
young age	0	6	5	4	1	5	2	4	27	1	1

Table 3. Development for different subgroups of terminal 6q deletions

Not specified = developmental delay is reported, but lacking sufficient information to classify reliably. See also Figure S1

Development categorised as normal (IQ >85), borderline (IQ 70-85), mild (IQ50-70), moderate (IQ 30-50) or severe (IQ <30) delay. The category with most individuals is highlighted in bold

Table 4. Age of achievement for milestones

	Total termin	al deletions	Deletions	<7.1 Mb	Deletions	>7.1 Mb
Milestones	Milestone achieved	Not able to perform milestone	Milestone achieved	Not able to perform milestone	Milestone achieved	Not able to perform milestone
Roll over	n=30	n=2	n=9	n=1	n=21	n=1
(weeks)	9 (2–28)	27.5 (25–30)	8 (4–10)*	25	10 (2–28)*	30
Sit up unaided	n=29	n=5	n=11	n=2	n=18	n=3
(months)	13 (7–40)	10 (6–28)	11 (7–18)*	8 (6–10)	15 (9–40)*	15 (7–28)
Pull up in a standing position	n=24	n=10	n=6	n=4	n=18	n=6
(months)	16.5 (9–72)	15 (6–57)	12.5 (9–18)*	11 (6–16)	18 (11–72)*	17 (7–57)
Walking unsupported	n=28	n=17	n=12	n=5	n=16	n=12
(months)	22.5 (14–57)	19 (6–393)	18 (14–30)	12 (6–16)	23.5 (15–57)	30.5 (7–393)
Speak first words	n=25	n=11	n=6	n=6	n=19	n=5
(months)	14 (9–60)	15 (6–86)	15.5 (10–30)	14 (6–44)	13 (9–60)	15 (7–86)
Speak two-word sentences	n=19	n=16	n=6	n=6	n=13	n=10
(months)	30 (18–72)	19.5 (6–86)	24 (20–45)	14 (6–44)	36 (18–72)	24 (7–86)
Fully toilet trained during the day	n=10	n=27	n=3	n=7	n=7	n=20
(years)	4.5 (3–10)	3.5 (0.5–32)	4 (3–4)	3.5 (0.5–8)	5 (4–10)	4 (0.5–32)

For each milestone the number of individuals who achieved the milestone and the median and range of their ages of achievement are given. The number of individuals who were not able to perform the milestone is also given and the median and range of the age at which they could not yet perform the milestone. Deletions smaller than 7.1 Mb include subgroups T-PSMB1, T-DLL1, T-AFDN and T-PDE10A, deletions larger than 7.1 Mb include subgroups T-QKI, T-PRKN, T-MAP3K4 and T-R.

* Significant (p<0.05) difference between the age of achievement for smaller (<7.1 Mb) and larger (>7.1 Mb) terminal deletions.

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license .



Total terminal deletions

Deletions <7.1 Mb

Deletions >7.1 Mb

age (years)



Walking independently





age (years)



Using two-word sentences





of patients